TECH.NASDAQBio-techne CORP

Form 4: BIO-TECHNE CEO Exercises Stock Options and Adjusts Holdings

Sentiment:

Statement of Changes in Beneficial Ownership

📋All filings for Bio-techne CORP
🔒Login to Follow

BIO-TECHNE Corp's CEO, Kim Kelderman, executed a routine transaction involving the exercise of stock options and a subsequent sale of shares for tax purposes.

Summary

  • On July 22, 2025, Kim Kelderman, Chief Executive Officer and Director of BIO-TECHNE Corp, acquired 48,176 shares of Common Stock through the exercise of stock options at an exercise price of $44.33 per share.
  • Concurrently, Kelderman disposed of 43,649 shares of Common Stock at a price of $53.12 per share, a common practice for covering tax obligations and exercise costs associated with option vesting.
  • Following these transactions, Kelderman's direct beneficial ownership of Common Stock stands at 46,730 shares.
  • The filing details various unexercised stock options and performance restricted stock units held by Kelderman, with exercise prices ranging from $47.60 to $120.46, and vesting schedules extending through August 2028.
  • A significant portion of these unvested awards, including Performance Restricted Stock Units and Performance Stock Options, are contingent on the achievement of specific performance goals, with vesting dates in August 2025, August 2026, and August 2027.

Sentiment

Score: 5

Explanation: The filing is a routine Form 4 detailing an executive's exercise of stock options and subsequent sale of shares for tax purposes. It does not indicate significant positive or negative sentiment beyond the standard course of executive compensation.

Positives

  • CEO Kim Kelderman continues to hold a substantial number of shares and unvested equity awards, aligning her long-term interests with those of shareholders.
  • The exercise of options indicates the realization of value from previously granted equity incentives, reflecting a standard component of executive compensation.

Negatives

  • A significant portion of the shares acquired through option exercise was immediately sold, which, while typical for tax purposes, reduces the net increase in the CEO's direct shareholding from the transaction.

Risks

  • The full vesting and value realization of Performance Restricted Stock Units and Performance Stock Options are contingent upon the achievement of specific performance goals, introducing a risk that these awards may not vest in full if targets are not met.
  • Future stock price fluctuations could impact the value of the remaining unexercised options and unvested restricted stock units.

Future Outlook

The CEO holds various unvested equity awards, including stock options and performance restricted stock units, with vesting schedules extending through August 2028 and expiration dates up to August 2034. The vesting of performance-based awards is contingent upon the achievement of specific performance goals, which will be certified by the Administrator.

Industry Context

This filing is a routine disclosure of insider transactions related to executive compensation, common across all industries for publicly traded companies. It does not provide specific insights into broader industry trends or the competitive landscape.

Related Party Transactions

  • The reported transactions involve the Chief Executive Officer and Director of BIO-TECHNE Corp, Kim Kelderman, exercising stock options and disposing of shares, which constitutes a related party transaction as it involves an insider's dealings with the company's securities.

Stakeholder Impact

  • Shareholders: The transaction is a routine part of executive compensation and does not directly impact other shareholders beyond the standard dilution from option exercises. It shows the CEO's continued equity stake.
  • Employees: No direct impact on employees.
  • Customers: No direct impact on customers.
  • Suppliers: No direct impact on suppliers.
  • Creditors: No direct impact on creditors.

Next Steps

  • Continued vesting of various stock options and restricted stock units for Kim Kelderman on specified future dates.
  • Certification of performance goals by the Administrator for performance-based equity awards.

Key Dates

DateDescription
08/06/2022Vesting date for 6,484 shares of Stock Option (Right to Buy) at $120.46.
08/06/2023Vesting date for 6,484 shares of Stock Option (Right to Buy) at $120.46.
08/15/2023Vesting date for 7,236 shares of Stock Options (Right to Buy) at $94.52.
08/15/2024Vesting date for 7,236 shares of Stock Options (Right to Buy) at $94.52.
08/15/2024Vesting date for 7,348 shares of Stock Options (Right to Buy) at $84.61.
11/01/2024Vesting date for 9,563 shares of Stock Options (Right to Buy) at $52.83.
02/01/2025Vesting date for 12,973 shares of Stock Options (Right to Buy) at $68.54.
07/22/2025Date of earliest transaction, involving the exercise of 48,176 stock options and disposition of 43,649 shares.
08/08/2025Expiration date for Stock Option (Right to Buy) at $44.33.
08/15/2025Vesting date for 6,984 Performance Restricted Stock Units, contingent on performance goals.
08/15/2025Vesting date for 21,704 Performance Stock Options (Right to Buy) at $94.52, contingent on performance goals.
08/15/2025Vesting date for 7,232 shares of Stock Options (Right to Buy) at $94.52.
08/15/2025Vesting date for 7,348 shares of Stock Options (Right to Buy) at $84.61.
08/15/2025Vesting date for 8,543 Restricted Stock Units.
08/15/2025Vesting date for 17,265 shares of Stock Options (Right to Buy) at $74.91.
11/01/2025Vesting date for 9,563 shares of Stock Options (Right to Buy) at $52.83.
02/01/2026Vesting date for 12,972 shares of Stock Options (Right to Buy) at $68.54.
08/07/2026Expiration date for Stock Option (Right to Buy) at $47.6.
08/15/2026Vesting date for 8,873 Performance Restricted Stock Units, contingent on performance goals.
08/15/2026Vesting date for 23,881 Performance Stock Options (Right to Buy) at $84.61, contingent on performance goals.
08/15/2026Vesting date for 7,236 shares of Stock Options (Right to Buy) at $94.52.
08/15/2026Vesting date for 7,347 shares of Stock Options (Right to Buy) at $84.61.
08/15/2026Vesting date for 8,543 Restricted Stock Units.
08/15/2026Vesting date for 17,265 shares of Stock Options (Right to Buy) at $74.91.
11/01/2026Vesting date for 9,563 shares of Stock Options (Right to Buy) at $52.83.
02/01/2027Vesting date for 12,973 shares of Stock Options (Right to Buy) at $68.54.
08/05/2027Expiration date for Stock Option (Right to Buy) at $66.97.
08/15/2027Vesting date for 9,423 Performance Restricted Stock Units, contingent on performance goals.
08/15/2027Vesting date for 25,945 Performance Stock Options (Right to Buy) at $68.54, contingent on performance goals.
08/15/2027Vesting date for 51,261 Performance Restricted Stock Units, contingent on performance goals.
08/15/2027Vesting date for 7,348 shares of Stock Options (Right to Buy) at $84.61.
08/15/2027Vesting date for 8,544 Restricted Stock Units.
08/15/2027Vesting date for 17,265 shares of Stock Options (Right to Buy) at $74.91.
11/01/2027Vesting date for 9,563 shares of Stock Options (Right to Buy) at $52.83.
02/01/2028Vesting date for 12,972 shares of Stock Options (Right to Buy) at $68.54.
08/06/2028Expiration date for Stock Option (Right to Buy) at $120.46.
08/15/2028Vesting date for 17,266 shares of Stock Options (Right to Buy) at $74.91.
08/15/2029Expiration date for Performance Stock Options (Right to Buy) at $94.52 and Stock Options (Right to Buy) at $94.52.
08/15/2030Expiration date for Performance Stock Options (Right to Buy) at $84.61 and Stock Options (Right to Buy) at $84.61.
11/01/2030Expiration date for Stock Options (Right to Buy) at $52.83.
02/01/2031Expiration date for Performance Stock Options (Right to Buy) at $68.54 and Stock Options (Right to Buy) at $68.54.
08/15/2034Expiration date for Stock Options (Right to Buy) at $74.91.

Keywords

BIO-TECHNE, TECH, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, CEO, Kim Kelderman, Equity Compensation, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.